


# RANGER II SFA PIVOTAL TRIAL

Prospective, Multi-Center, Randomized Controlled Trial  
Ranger™ Drug-Coated Balloon vs. Uncoated Balloon (3:1). Follow-up through 5-Years



**Ranger DCB demonstrated exceptional outcomes at 1, 2, and 3 years.**




\* Kaplan-Meier Estimate: Primary patency as determined by duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) is  $\leq 2.4$  at the 12-month follow-up visit, in the absence of clinically driven TLR or bypass of the target lesion.

\*\* At risk denotes the number of subjects entered in the calculation at the time interval.


## Ranger DCB demonstrated durability, with low reintervention rates through 5 years<sup>4</sup>

### K-M FREEDOM FROM CD-TLR

**94.5% at 1-Year<sup>†</sup>**  
More than 9 in 10 patients did not need reintervention at 1 year



**76.9% at 5-years<sup>‡</sup>**  
Nearly 8 in 10 patients did not need reintervention at 5 years



<sup>†</sup>Subjects at risk at day 365=198 subjects

<sup>‡</sup>Subjects at risk at day 1825=68 subjects

<sup>1</sup> RANGER II SFA RCT 1-Year Results published in JACC:CI. doi.org/10.1016/j.jcin.2021.03.021

<sup>2</sup> RANGER II SFA RCT 2-Year Results presented by Ravish Sachar, MD, VIVA 2021

<sup>3</sup> RCT update presented by Marianne Brodmann, MD at LINC 2023

<sup>4</sup> Latest RCT update presented by Marianne Brodmann, MD at LINC 2024

## 1-YEAR PRIMARY ENDPOINT RESULTS<sup>1</sup>

<b>Primary Safety Endpoint</b> (Freedom from MAE)
<b>Primary Effectiveness Endpoint</b> (Binary Primary Patency)

Ranger™ DCB (n=278)	PTA (n=98)	p-value
94.1% (241/256)	83.5% (76/91)	$P_{\text{non-inferiority}} < 0.0001$
82.9% (194/234)	66.3% (57/86)	0.0017

## BASELINE PATIENT & LESION CHARACTERISTICS

<b>Age (Year)</b>
<b>Women</b>
<b>Smoking History</b>
<b>Current/Previous</b>
<b>Never/Unknown</b>
<b>Diabetes Mellitus</b>
<b>Lesion Length (mm)</b>
<b>Moderate Calcium (PACSS Grade 3)</b>
<b>Severe Calcium (PACSS Grade 4)</b>
<b>100% (Occlusion)</b>

Ranger™ DCB (n=278)	PTA (n=98)	p-value
70.6	69.1	0.1887
37.8%	31.6%	0.2769
31.3%/54.0%	45.9%/38.8%	N/A
14.4%/0.4%	15.3%/0.0%	N/A
42.4%	43.9%	0.8055
82.5	79.9	0.6551
36.3%	52.0%	0.0064
11.5%	10.2%	0.7240
18.3%	29.6%	0.0193

## 1-YEAR KEY RESULTS<sup>1</sup>

<b>CD-TLR</b>
<b>K-M All-Cause Mortality</b>

Ranger™ DCB (n=278)	PTA (n=98)	p-value
5.5%	16.5%	0.0011
1.9%	2.1%	0.8794*

## 2-YEAR KEY RESULTS<sup>2</sup>

<b>K-M Freedom from TLR</b>
<b>Mod/Sev Calcium Subgroup K-M Freedom from TLR</b>
<b>CTO Subgroup K-M Freedom from TLR</b>
<b>All-Cause Mortality</b>

Ranger™ DCB (n=278)	PTA (n=98)	p-value
87.4%	79.5%	0.0316*
90.9%	79.6%	0.0246*
85.6%	62.8%	0.0172*
5.7%	3.2%	0.4218

## KEY LONG-TERM RESULTS<sup>3,4</sup>

<b>3-YEAR RESULTS</b>
<b>K-M Primary Patency</b>
<b>5-YEAR RESULTS</b>
<b>All-Cause Mortality</b>
<b>K-M Freedom from CD-TLR</b>
<b>Major Amputation</b>

Ranger™ DCB (n=278)	PTA (n=98)	p-value
77.4%	73.5%	0.2555*
15.8% (44/278)	20.4% (20/98)	0.2995
76.9%	74.8%	0.3715*
0.5%	0.0%	1.0000

\*Log-rank p-value

<sup>1</sup>RANGER II SFA RCT 1-Year Results published in JACC:CI. doi.org/10.1016/j.jcin.2021.03.021 <sup>2</sup>RANGER II SFA RCT 2-Year Results presented by Ravish Sachar, MD. VIVA 2021 <sup>3</sup>RCT update presented by Marianne Brodmann, MD at LINC 2023 <sup>4</sup>Latest RCT update presented by Marianne Brodmann, MD at LINC 2024

### RANGER DRUG COATED BALLOON

**CAUTION:** Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete "Instructions for Use" for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator's Instructions. **INTENDED USE/INDICATIONS FOR USE** The Ranger Drug Coated Balloon (DCB) is indicated for percutaneous transluminal angioplasty (PTA) of de novo or restenotic lesions up to 180 mm in length located in native superficial femoral and proximal popliteal arteries (SFA/PPA) with reference vessel diameters of 4 mm to 7 mm. **CONTRAINDICATIONS** Use of the Ranger DCB is contraindicated in: • Patients with known hypersensitivity to paclitaxel (or structurally-related compounds). • Patients who cannot receive recommended antiplatelet and/or anticoagulation therapy. • Women who are breastfeeding, pregnant, or men intending to father children. • Patients judged to have a lesion that prevents complete inflation of an angioplasty balloon or proper placement of the delivery system. • Coronary arteries, renal arteries, and supra-aortic/cerebrovascular arteries. **WARNINGS** • To reduce the potential for vessel damage, the inflated diameter of the balloon should approximate the diameter of the vessel segment to be treated. The inflated length of the balloon (shoulder to shoulder) may exceed the length of the lesion/stenosis by approximately 10 mm on either side within the targeted artery. • The safety of using multiple Ranger DCBs with a total drug dosage exceeding 9266 µg of Paclitaxel in a patient has not been studied. • Using a drug-eluting stent in conjunction with Ranger DCB at the same treatment site has not been studied. **PRECAUTIONS** • The balloon catheter should be used only by physicians trained in the performance of percutaneous transluminal angioplasty. • The balloon catheter should be used with caution for procedures involving calcified lesions due to the abrasive nature of these lesions. • The balloon catheter is not intended for injection of contrast medium. • Full arterial wall apposition of the Ranger DCB is necessary for proper drug transfer to the vessel. • Do not touch, wipe, bend, or squeeze the balloon. Do not allow it to contact any liquids including organic solvents such as alcohol or detergents prior to insertion. Damage to the balloon coating or premature release of the drug may occur. • This product should not be used in patients with uncorrected bleeding disorders or patients who cannot receive anticoagulation or antiplatelet aggregation therapy. • If treating a long lesion (longer than the maximum balloon length available), each individual segment should be treated only once with a drug-coated balloon. Treat each segment with a new balloon and minimize overlapping of treated segments. **PREGNANCY / LACTATION** • This product has not been tested in pregnant or breastfeeding women or in men intending to father children; effects on the developing fetus have not been studied and the risks and reproductive effects remain unknown. • It is not recommended that the Ranger DCB be used in women attempting to conceive, or who are pregnant. • Prior to use, careful consideration should be given to the continuation of breastfeeding, taking into account the importance of the procedure to the mother. It is not known whether paclitaxel is distributed in human milk. In lactating rats, milk concentrations appeared to be higher than maternal plasma levels and declined in parallel with the maternal levels. Mothers should be advised of the potential for serious adverse reactions to paclitaxel in nursing infants. **DRUG INFORMATION** The mechanism of action by which paclitaxel reduces or reverses neointima formation and proliferation, leading to restenosis, as demonstrated in clinical studies has not been established. It is known that paclitaxel promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. **DRUG INTERACTION** Possible interactions of paclitaxel with concomitantly administered medications have not been formally investigated. Drug interactions of systemic chemotherapeutic levels of paclitaxel with possible concomitant medications are outlined in the labeling for finished pharmaceuticals containing paclitaxel, such as TAXOL™. **CARCINOGENICITY, GENOTOXICITY, AND REPRODUCTIVE TOXICOLOGY** No long-term studies in animals have been published in peer-reviewed literature to evaluate the carcinogenic potential of paclitaxel. Paclitaxel interacts with microtubules; this is the major mechanism by which it inhibits cell growth. One consequence is the loss of whole chromosomes via interactions with spindle microtubules during cell division. As such, paclitaxel is defined as an aneuploid (agent causing an alteration in chromosome number). This indirect action is consistent with positive responses in vitro and in vivo micronucleus genotoxicity assays, which detect DNA fragments. Positive results have also been reported for chromosomal aberrations in primary human lymphocytes. It is not known whether paclitaxel has a separate direct action on DNA in the generation of DNA strand breaks or fragments. It is negative in assays for gene mutation, including salmonella and CHO/HPRT. Paclitaxel administered via IV prior to and during mating produced impairment of fertility in male and female rats at doses > 1 mg/kg. Administration of paclitaxel during the period of organogenesis to rabbits at doses of 3 mg/kg/day caused embryo- and fetotoxicity. Maternal toxicity was also observed at this dose. No teratogenic effects were observed at 1 mg/kg/day; teratogenic potential could not be assessed at higher doses due to extensive fetal mortality. For comparison, the worst-case dose of paclitaxel delivered by the Ranger DCB (assuming maximum size and number of balloons used in a lesion) is 9266 µg, which is approximately 6 and 19 times less than the dose that saw effects in rats and rabbits, respectively, when normalizing to body weight. **PRE AND POST PROCEDURE ANTIPLATELET THERAPY** It is strongly advised that the treating physician follow the Inter-Society Consensus (TASC II) Guidelines recommendations (or other applicable country guidelines) for antiplatelet therapy pre- and postprocedure. **ADVERSE EVENTS** Potential adverse events include, but are not limited to, the following: • Allergic reaction (device, contrast medium, medications) • Arteriovenous fistula • Death • Hematoma • Hemorrhage/Bleeding • Hypotension/Hypertension • Infection/Sepsis • Pseudoaneurysm • Thromboembolic episodes • Vascular thrombosis • Vessel injury (e.g., dissection, perforation, rupture) • Vessel occlusion • Vessel spasm **POTENTIAL ADVERSE EVENTS NOT CAPTURED ABOVE THAT MAY BE UNIQUE TO THE PACLITAXEL DRUG COATING:** • Allergic/immunologic reaction to drug (paclitaxel or structurally-related compounds) or coating or its individual components • Alopecia • Anemia • Blood product transfusion • Gastrointestinal symptoms • Hematologic dyscrasia (including leukopenia, neutropenia, thrombocytopenia) • Hepatic enzyme changes • Histologic changes in vessel wall, including inflammation, cellular damage or necrosis • Myalgia/Arthralgia • Peripheral neuropathy • Apart from hypersensitivity reactions (allergic/immunologic reactions), the likelihood of paclitaxel related adverse events is low, due to the low exposure. There may be other potential adverse events that are unforeseen at this time. 92618589 C.3

Ranger is a registered or unregistered trademark of Boston Scientific Corporation or its affiliates. All other trademarks are property of their respective owners.

**Boston Scientific**  
Advancing science for life™

**Peripheral Interventions**  
300 Boston Scientific Way  
Marlborough, MA 01752-1234  
bostonscientific.com

To order product or for more information contact customer service at 1.888.272.1001

© 2024 Boston Scientific Corporation or its affiliates. All rights reserved.

PI-1612607-AB